XSHE
003042
Market cap303mUSD
Oct 09, Last price
14.38CNY
1D
0.98%
1Q
15.32%
IPO
-45.28%
Name
Shandong Sino-Agri United Biotechnology Co Ltd
Chart & performance
P/E
—
P/S
1.10
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.35%
Rev. gr., 5y
2.75%
Revenues
1.86b
-7.58%
Net income
-137m
L+11.56%
CFO
15m
-85.35%
Dividend
Jun 21, 20230.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Sino-Agri United Biotechnology Co., Ltd. engages in the research and development, production, and sales of pesticide production in the whole industry chain, such as pesticide intermediates, technical and preparation products. Its products include imidacloprid, acetamiprid, nitenpyram, pyridaben and other pesticide raw materials, intermediates and pesticides, fungicides, and herbicides. The company was founded on December 19, 2006 and is headquartered in Jinan, China.
Key people
Jinhong Liu
Chairman of the Board · since 2025
Qiang Li
Chief Financial Officer · since 2022
Ning Li
General Manager, Director · since 2025
Hongsheng Jiang
Deputy General Manager · since 2024
Wenli Wang
Deputy General Manager · since 2022
Baoxiu Zhao
Deputy General Manager, Director · since 2025
Jianfeng Tang
Chief Engineer · since 2022
Shijin Yan
Deputy General Manager, Secretary of the Board · since 2024
Yan Han
Director · since 2020
Yan Li
Director · since 2025
Xin Zhang
Staff Elected Director · since 2025
Gongyong Wang
Independent Director · since 2022
Yuanchao Wu
Independent Director · since 2022
Independent Director · since 2024
Headquarters & legal address
中国(山东)自由贸易试验区济南片区经十路9999号黄金时代广场A座14层
济南市, SD 250000
CN
济南市, SD 250000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||